A Phase I Trial of Ipilimumab (Anti CTLA- 4 Antibody) in Combination With Lenalidomide (IMiD) in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2019
At a glance
- Drugs Ipilimumab (Primary) ; Lenalidomide
- Indications Adenocarcinoma; Adrenocortical carcinoma; Cancer; Hodgkin's disease; Leiomyosarcoma; Malignant melanoma; Renal cancer; Thyroid cancer
- Focus Adverse reactions
- 21 Feb 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 07 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.